Evidence map›Paper›PMID 40952135›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2026

Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.

Qihang Ding, Wenhao Li, Ling Mei, Suling Luo, Jing Tao, Chongxiu Shi, Hongping Yang, Wei Feng, Yungchang Chen, Yu Chen and 2 more

Abstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qihang DingEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.ORCID 0000-0002-2665-9036
Wenhao LiEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Ling MeiEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Suling LuoHealth Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
Jing TaoEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Chongxiu ShiEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Hongping YangEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Wei FengMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 2000444, China.
Yungchang ChenDepartment of Medical Oncology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, 610041, China.
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 2000444, China.ORCID 0000-0002-8206-3325
Jong Seung KimDepartment of Chemistry, Korea University, Seoul, 02841, South Korea.
Xue ShenEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.

Funding

China Scholarship Council CSC 202106270027 to Q.DChinese Southwest Oncology Group, Clinical Research CSWOG202101002Chinese Southwest Oncology Group, Clinical Research CSWOG202101004Gansu Science and Technology Major Project 23ZDFA014Health Commission of Sichuan Province, Science and Technology Project 23LCYJ025Jiangsu Xiansheng Zaiming Pharmaceutical Co., LtdNational Natural Science Foundation of China U2267221Open Subject Funding of Sichuan Engineering and Technology Research Center for Industrialization of Antiviral Chinese Medicines of Sichuan Guangda Pharmaceutical Co., Ltd KT2024-002Open Subject Funding of Sichuan Engineering and Technology Research Center for Industrialization of Antiviral Chinese Medicines of Sichuan Guangda Pharmaceutical Co., Ltd KT2024-003Shandong Laboratory Program SYS202205State Key Laboratory of Drug Research, Chinese Academy of Sciences SIMM0120231004Strategic Priority Research Program of the Chinese Academy of Sciences XDB0830300
6 · The paper itself

Abstract

Advanced metal-based nanomaterials (MBNs) represent a dynamic frontier in nanomedicine, offering a versatile platform for next-generation diagnostics and therapeutics. Their tunable structures and catalytic, optical, and magnetic properties enable diverse nanodynamic therapies (NDTs), including photodynamic, chemodynamic, sonodynamic, thermodynamic, piezoelectric, radiodynamic, and magnetodynamic modalities. In addition to the well-established tumor ablation, MBNs also feature potent antimicrobial and antiviral activity, functioning via reactive oxygen species generation, immune modulation, and biofilm disruption. Recent developments in metal-organic frameworks, metal-phenolic networks, and 2D metal nanosheets have expanded the toolkit for precision drug delivery, imaging-guided therapy, and bioresponsive release strategies. This comprehensive review highlights the structural design principles, therapeutic mechanisms, and versatile biomedical applications of emerging MBN platforms, emphasizing synergistic treatment strategies and their role in overcoming hypoxia, multidrug resistance, and immunosuppression. Despite their promise, clinical translation remains hindered by unresolved issues in long-term biosafety, biodegradation, and scalable manufacturing. Future efforts are expected to focus on tailoring intelligent nanostructures with optimized pharmacokinetics, integrating multimodal imaging with real-time therapeutic feedback, and ensuring regulatory compliance. Continued innovation at the interface of materials science, biology, and medicine will be essential for transforming MBN-based systems into clinically viable tools for oncology, infectious disease control, and personalized medicine.

Indexed as

MetalsNanomedicineNanostructuresTheranostic NanomedicineAnimalsHumansMetal-Organic FrameworksNeoplasmsMetal-Organic FrameworksMetalsdrug deliverymetal‐based nanomaterialsmolecular imagingnanodynamic therapytheranostics

Identifiers

PMID40952135
PMCPMC12759226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.